

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee: Steven A. Kliewer et al.

Patent No.: 7,238,491

Issued: July 3, 2007

Serial No.: 09/276,935

For: An Orphan Nuclear Receptor

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR 1.322

Attention Certificate of Corrections Branch
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed please find a certificate of correction in connection with the above-identified patent.

This request is made in order to correct the mistakes incurred through the fault of the Patent Office. A explanation of the errors is as follows:

1. The title is incorrect.
2. Claims 28 and 29 are allowed by the Examiner, but omitted from the printing of the patent. This document requests that claims 4-16 be renumbered as 6-18 and omitted claims 28 and 28 (now 4 and 5) be inserted.

Please charge any shortage in the fees or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,

/Michael M. Conger/
Michael M. Conger
Registration No. 43,562
Attorney for Patentee

Dated: May 14, 2008
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property Dept.
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-2474; Facsimile: (919) 483-7988

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,238,491

Page 1 of 1

APPLICATION NO. : 09/276,935

ISSUE DATE : July 3, 2007

INVENTOR(S) : Steven A. Kliewer, Stacey A. Jones, Timothy M. Willson

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please correct the title to read "An Orphan Nuclear Receptor"

Please re-number claims 4-16 as 6-18

Please insert the following allowed claims 4 and 5 (originally numbered 28 and 29).

4. The method according to claim 1 wherein said protein has an amino acid sequence including amino acids 130 to 434 of SEQ ID NO: 14.

5. The method according to claim 1 wherein said protein shares at least 98% amino acid sequence identity with the ligand binding domain of SEQ ID NO: 14 and retains the sequence's ligand-binding function.

MAILING ADDRESS OF SENDER (Please do not use customer number)

GLAXOSMITHKLINE
Corporate Intellectual Property
Mai B475, Five Moore Drive
P. O. Box 13398
Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of corrections Branch, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450**

If you need assistance in completing this form, call 1-800-PTO-9199 and selection option 2.